EzWay Transfection Reagent

Catalog Number	K21000
Size	0.5ml
Type	Buffer & Reagent
Datasheet

Specification

EzWay™ Transfection Reagent, consisting of a unique cationic lipid has appropriate DNA-binding affinity for reliable gene transfection that is applicable to both preclinical and nonclinical studies. Preparing the liposome-DNA complex (lipoplex) is very easy and rapid.
Also, EzWay™ Transfection Reagent shows relatively stronger DNA-binding affinity and better transfection efficiency than other liposomal reagents.
Sufficient reagent for 250 transfection in a 24-well plate is provided.

Cationic lipid liposome-based reagent
Low cellular toxicity
Efficient siRNA and plasmid DNA delivery
Transfection of a wide variety of cell types
High transfection efficiency of stable and transient transfections
Effective in both serum-containing medium and serum-free medium
Ready-to-use reagent
Simple protocol
Universal use for both in vivo and in vitro

Protocol

Applications

List of cell lines successfully transfected with EzWayTM Transfection Reagent

Cell Line	Cell Type
HeLa	Human cervix adenocarcinoma
293A	Human kidney cancer
B16BL6	Mouse skin melanoma
B16F10	Mouse skin melanoma
MCF-7	Human breast adenocarcinoma
HepG2	Human liver/hepatocellular carcinoma
Hep-3B	Human hepatocellular carcinoma
Chang	Human normal liver cell
BT-20	Human breast carcinoma
TC-1	Mouse lung tumor
CT-26	Mouse colon carcinoma
EMT-6	Mouse breast cancer
SK-OV-3	Human ovarian adenocarcinoma
A549	Human lung epithelial carcinoma
MDA-MB-231	Human breast adenocarcinoma
NCI	Human lung cancer (carcinoma)
SK-Br-3	Human breast carcinoma
HT-29	Human colorectal adenocarcinoma
Jurkat	Human T-cell leukemia

Efficient delivery of DNA to a wide variety of cell lines

(A)

(B)

Using the EzWay™ Transfection Reagent or competitor reagent L, cells were transfected with the pDNA, which expresses luciferase (A) and GFP (B) respectively. One microgram of pDNA complexed to EzWay ™(1:4.9 wt ratios of pDNA and lipid) was added to a various cell lines, The cells were transfected for 4 hours and incubated for additional 24 hours. The luciferase activity (A) of the cell lysate was measured with a luminometer and a luciferase assay kit and the GFP expression (B) was determined by fluorescence microscopy.

Knockdown efficacy of EzWay™ Transfection Reagent

siRNA targeting luciferase was transfected by EzWay™ Transfection Reagent and competitor reagent L into Hep-3B cells. For B16BL6 cells, siRNA targeting luciferase was co-transfected with luciferase gene by two products, respectively. Luciferase-silencing efficiency was calculated relative to untreated cells. (A) shows the luciferase expression, while (B) shows the reduction in luciferase activity. EzWay™ Transfection Reagent delivered significant gene silencing from 10 nM of renilla luciferase siRNA.

Inhibition of GFP expression in cells transfected with GFP targeting siRNA using EzWay™ Transfection Reagent

MDA-MB-231 cells constitutively expressing the GFP gene were transfected with 10 nM final siRNA concentration of GFP-targeting siRNA.